These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 2140392)
41. Limited tryptic cleavage of complement factor H abrogates recognition of sialic acid-containing surfaces by the alternative pathway of complement. Koistinen V Biochem J; 1992 Apr; 283 ( Pt 2)(Pt 2):317-9. PubMed ID: 1533511 [TBL] [Abstract][Full Text] [Related]
42. C3b2-IgG complexes retain dimeric C3 fragments at all levels of inactivation. Jelezarova E; Luginbuehl A; Lutz HU J Biol Chem; 2003 Dec; 278(51):51806-12. PubMed ID: 14527961 [TBL] [Abstract][Full Text] [Related]
43. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127 [TBL] [Abstract][Full Text] [Related]
44. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. I. Isolation and characterization of factor H: the serum cofactor for the C3b/C4b inactivator (factor I). Kinoshita T; Nussenzweig V J Immunol Methods; 1984 Jul; 71(2):247-57. PubMed ID: 6376638 [TBL] [Abstract][Full Text] [Related]
45. Accelerated decay of C3b to iC3b when C3b is bound to the Cryptococcus neoformans capsule. Pfrommer GS; Dickens SM; Wilson MA; Young BJ; Kozel TR Infect Immun; 1993 Oct; 61(10):4360-6. PubMed ID: 8406826 [TBL] [Abstract][Full Text] [Related]
46. Mechanism of resistance to lysis by the alternative complement pathway in Trypanosoma cruzi trypomastigotes: effect of specific monoclonal antibody. Schenkman S; Güther ML; Yoshida N J Immunol; 1986 Sep; 137(5):1623-8. PubMed ID: 2943798 [TBL] [Abstract][Full Text] [Related]
47. Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces. Carreno MP; Labarre D; Maillet F; Jozefowicz M; Kazatchkine MD Eur J Immunol; 1989 Nov; 19(11):2145-50. PubMed ID: 2480904 [TBL] [Abstract][Full Text] [Related]
49. Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factors H and I. Pangburn MK; Müller-Eberhard HJ Biochemistry; 1983 Jan; 22(1):178-85. PubMed ID: 6219696 [No Abstract] [Full Text] [Related]
50. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. Pangburn MK J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425 [TBL] [Abstract][Full Text] [Related]
51. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1. Nilsson-Ekdahl K; Nilsson B Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329 [TBL] [Abstract][Full Text] [Related]
52. Pattern of degradation of human complement fragment, C3b. Sim E; Wood AB; Hsiung LM; Sim RB FEBS Lett; 1981 Sep; 132(1):55-60. PubMed ID: 6457754 [No Abstract] [Full Text] [Related]
53. Epstein-Barr virus regulates activation and processing of the third component of complement. Mold C; Bradt BM; Nemerow GR; Cooper NR J Exp Med; 1988 Sep; 168(3):949-69. PubMed ID: 2844953 [TBL] [Abstract][Full Text] [Related]